We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo ADLM 2026 Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Inverness to Acquire Applied Biotech from Apogent

By HospiMedica staff writers
Posted on 19 Aug 2003
In a move to improve the company's position in point-of-care diagnostics, Inverness Medical Innovations, Inc. (Waltham, MA, USA) will acquire Applied Biotech, Inc. (San Diego, CA, USA) from Apogent Technologies, Inc. (Portsmouth, NH).

Under the terms of the agreement, Inverness will acquire all of the stock of Applied Biotech in exchange for 692,506 shares of its common stock and additional consideration of either a payment of US$13.4 million in cash or a payment of $5 million in cash and a one-year $8.4 million subordinated promissory note. Applied Biotech develops, manufactures, and markets rapid diagnostic products in the area of women's health, infectious diseases, and drugs of abuse. Inverness is a provider of women's health products and other consumer and point-of-care health products.

"The addition of Applied Biotech is a continuation of our efforts towards establishing a preeminent position in the field of point-of-care diagnostics,” said Ron Zwanziger, CEO of Inverness Medical Innovations. "We expect to benefit from product and distribution synergies with our Wampole business and, post-integration, the acquisition is likely to be accretive to earnings.”




Related Links:
Inverness
Applied Biotech
Apogent

Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Online QC Software
Acusera 24•7
HPV Test
Allplex HPV28 Detection
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]

Latest Industry News

Collaboration Advances Extracellular Vesicle-Based Tests for Neurodegenerative Diseases
19 Aug 2003  |   Industry

Tempus to Acquire Personalis in $1.5 Billion Precision Oncology Deal
19 Aug 2003  |   Industry

Bruker Expands NGS Capabilities for Sepsis and Bloodstream Infections
19 Aug 2003  |   Industry



PURITAN MEDICAL